{"analyses":[{"ciLowerLimit":"0.86","ciPctValue":"95","ciUpperLimit":"1.17","estimateComment":"Temozolomide events (deaths) = 320. Dacarbazine events (deaths) = 325.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9999","paramType":"Hazard Ratio (HR)","paramValue":"1.00","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.11","upperLimit":"9.89","value":"9.13"},{"groupId":"OG001","lowerLimit":"8.21","upperLimit":"10.28","value":"9.36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"429"},{"groupId":"OG001","value":"430"}],"units":"Participants"}],"description":"Overall Survival was defined as the time from the date of randomization to the date of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (\"7 days on / 7 days off\" continuously)","id":"OG000","title":"Temozolomide"},{"description":"dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks","id":"OG001","title":"Dacarbazine"}],"paramType":"MEDIAN","populationDescription":"Intent to Treat Population","reportingStatus":"POSTED","timeFrame":"The final analysis was to be performed when at least 616 deaths had occurred.","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"Months"}